Seed oil of Brucea javanica induces apoptosis through the PI3K/Akt signaling pathway in acute lymphocytic leukemia Jurkat cells / 中国天然药物

Brucea javanica oil emulsion (BJOE) has been used to treat tumor in China for more than 40 years. However, its components and effectiveness in the treatment of acute lymphocytic leukemia (ALL) and its mechanism of anti-cancer activity remain unknown. In the current study, high-performance liquid chromatography-evaporative light scattering detector (HPLC-ELSD) was used to analyze the components of BJOE. Then, the anti-leukemia effects of BJOE were examined both in vitro and in vivo using ALL Jurkat cells and the p388 mouse leukemia transplant model, respectively. The primary ALL leukemia cells were also used to confirm the anti-leukemia effects of BJOE. The apoptotic-related results indicated that BJOE induced apoptosis in Jurkat cells and were suggestive of intrinsic apoptotic induction. Moreover, BJOE inhibited Akt (protein kinase B) activation and upregulated its downstream targets p53 and FoxO1 (forkhead box gene, group O-1) to initiate apoptosis. The activation of GSK3β was also involved. Our findings demonstrate that BJOE has anti-leukemia effects on ALL cells and can induce apoptosis in Jurkat cells through the phosphoinositide3-kinase (PI3K) /Akt signaling pathway.

Brusatol: A potential anti-tumor quassinoid from Brucea javanica / 中草药·英文版

Brusatol, a triterpene lactone compound mainly from Brucea javanica, sensitizes a broad spectrum of cancer cells. It is known as a specific inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway. In this review, we provide a comprehensive overview on the antitumor effect and molecular mechanisms of brusatol in vitro and in vivo. This review also covers pharmacokinetics studies, modification of dosages forms of brusatol. Increasing evidences have validated the value of brusatol as a chemotherapeutic agent in cancers, which may contribute to drug development and clinical application.

Clinical observation of Brucea javanica oil emulsion injection combined with S-1 for treatment of elderly patients with advanced gastric cancer / 肿瘤研究与临床

Objective@#To observe the efficacy and safety of Brucea javanica oil injection combined with S-1 in the treatment of elderly patients with advanced gastric cancer.@*Methods@#The clinical data of 62 elderly patients with advanced gastric cancer who were admitted to Shanxi Provincial Cancer Hospital from May 2017 to May 2018 were retrospectively analyzed. Thirty-one patients in the control group treated with S-1 alone, and 31 patients in the observation group treated with S-1 combined with Brucea oil emulsion injection. The clinical efficacy, adverse reactions, immune function and quality of life of the two groups were compared.@*Results@#The total effective rates of the observation group and the control group were 70.97% (22/31) and 48.39% (15/31), respectively, and the difference was statistically significant (χ 2 = 11.889, P < 0.01). The incidence rates of gastrointestinal reaction and peripheral neurotoxicity in the observation group were 9.68% (3/31) and 3.23% (1/31), and the rates in the control group were 35.48% (11/31) and 25.81% (8/31), respectively, the differences between the two groups were statistically significant (both P < 0.05); the incidence rates of hepatotoxicity, nephrotoxicity and myelosuppression in the observation group were 3.23% (1/31), 3.23% (1/31), and 3.23% (1/31), and the rates in the control group were 22.58% (7/31), 16.13% (5/31), and 12.90% (4/31), respectively, and the differences between the two groups were not statistically significant (all P > 0.05). The Karnofsky scores of the observation group and the control group after treatment were (92±4) points and (86±3) points, respectively, and the difference was statistically significant (t = -2.075, P = 0.042). The serum levels of interleukin-2 (IL-2) and interferon-γ in the observation group after treatment were (38±4) ng/L and (51±4) ng/L, and the levels in the control group were (31±3) ng/L and (40±4) ng/L, respectively, and the differences were statistically significant (t values were -2.097 and -2.293, both P < 0.05), and the serum levels of IL-4, IL-6 and IL-10 in the observation group after treatment were (42±5) ng/L, (34±4) ng/L and (22±2) ng/L, and the levels in the control group were (59±6) ng/L, (50±5) ng/L and (30±3) ng/L, respectively, and the differences were statistically significant (t values were 2.109, 2.867 and 4.278, all P < 0.05). There was no statistical difference in the serum levels of tumor necrosis factor-α between the observation group and the control group after treatment (t = -0.922, P = 0.360).@*Conclusion@#Compared with monotherapy of S-1, the treatment of Brucea javanica oil emulsion injection combined with S-1 can improve the clinical efficacy, reduce the incidence of adverse reactions, enhance the immune function and effectively improve the quality of life of elderly patients with advanced gastric cancer.

Formulation development and evaluation of gastroretentive floating beads with Brucea javanica oil using ionotropic gelation technology / 中国天然药物

In the present study, a gastric retention floating system for Brucea javanica oil, composed of alginate and carrageenan, was prepared using ionotropic gelation. Parameters for floatability, drug load, encapsulation efficiency, bead morphology, in vitro release, and in vivo gastric retention were evaluated. The optimized formulation via Box-Behnken design consisted of 1.7% alginate (W/V), 1.02% carrageenan (W/V), 1.4% CaCO (W/V), and a gelling bath of pH 0.8. The alginate-carrageenan-Brucea javanica oil beads had a porous structure and exhibited up to 24 h of in vitro floatability with a load capacity of 45%-55% and an encapsulation efficiency of 70%-80%. A 6-h sustained release was observed in vitro. The beads had a prolonged gastric retention (> 60% at 6 h) in fasted rats, compared to non-floating beads (15% at 6 h), as measured by gamma scintigraphy with single-photon emission tomography/computed tomography (SPET/CT). In conclusion, the alginate-carrageenan-Brucea javanica oil system showed enhanced oil encapsulation efficiency, excellent floating and gastric retention abilities, and a favorable release behavior.

Effect of brucea javanica oil emulsion on hypertrophic scar fibroblasts proliferation and its mechanism / 中华整形外科杂志

Objective@#To investigate the effect of brucea javanica oil emulsion (BJOE) on the proliferation, collagen synthesis and ERK1/2 MAPK singaling pathway of hypertrophic scar fibroblasts (HSFs).@*Methods@#The human hypertrophic scar tissues were collected, and HSFs were isolated, cultured and identified in vitro. Cells were treated with BJOE under the concentration of 0.5, 1, 5, 10, 20 and 50 mg/ml for 24 h respectively; the half inhibitory concentration(IC50)of 24 h was calculated. The experimental groups were treated for 24, 48, 72 h by BJOE at the IC50, the control group was conventionally cultured without BJOE. Cell proliferation was detected by CCK-8 assay and cell cycle was determined by flow cytometry (FCM). The morphological changes of cells treated with BJOE at a concentration of IC50 for 24 h were observed. The protein expression levels of collagen Ⅰ, vimentin, ERK1/2 and p-ERK1/2 were measured by Western blot.@*Results@#The IC50 of BJOE was 1.176 mg/ml, so the concentration of 1 mg/ml was selected for the subsequent experiment. After 24, 48, 72 h treated with BJOE at a concentration of 1 mg/ml, the inhibition rates of BJOE on HSFs were (53.13±2.40)%, (75.07±2.67)%and (88.65±0.32)%, respectively. The difference was significant (P<0.05). Under the effect of BJOE, the number of HSFs significantly decreased, the interval between cells widened, cell protrusions were significantly shortened or even disappeared, and the cells became round. The percentage of cells decreased in S phase. Expression of type Ⅰ collagen, vimentin and p-ERK1/2 in HSF was significantly inhibited (P<0.05), while there was no significant difference in the expression of ERK1/2(P>0.05).@*Conclusions@#BJOE inhibites the proliferation of HSF and the synthesis of type Ⅰ collagen, and its mechanism is related to the inhibition of ERK1/2 phosphorylation and vimentin expression.

Preparation and evaluation of paclitaxel and Brucea javanica oil core-matched nanoemulsions to treat cancer in vitro and in vivo / 中草药·英文版

Objective: Developed the core-matched nanoemulsions (CMNEs) to co-delivery paclitaxel-oleic acid (PTX-OA) prodrug and Brucea javanica oil (BJO) for increasing the antitumor effect. Methods: Antitumor effects and mechanism of PTX-OA/BJO CMNEs that the combination therapy which based on core-matched technology (CMT) were evaluated in vitro and in vivo. Results: The PTX-OA/BJO CMNEs were of nanoscale particle size (108.7 ± 2.3) nm and with entrapment efficiency of >95%. The PTX-OA/BJO CMNEs displayed concentration and time-dependent cytotoxicity against HepG-2 cells and increased G2/M phase block. More importantly, a significant reduction of the tumor volume with no obvious toxicity was observed in nude mice model following administration of PTX-OA/BJO CMNEs compared with the control treated with normal saline (P < 0.05), which suggested the excellent efficacy in vivo. It was further found that the enhanced effectiveness of PTX-OA/BJO CMNEs were associated with the ability of inducing apoptosis of the tumor cells, as well as obviously inhibiting tumor cell proliferation and the activity of TOPO Ⅱ. Conclusion: Co-encapsulation of two drugs with different mechanisms allows simultaneous interruption of diverse anticancer pathways, resulting in increased therapeutic response and lower toxicity.

Formulation development and evaluation of gastroretentive floating beads with Brucea javanica oil using ionotropic gelation technology / 中国天然药物

In the present study, a gastric retention floating system for Brucea javanica oil, composed of alginate and carrageenan, was prepared using ionotropic gelation. Parameters for floatability, drug load, encapsulation efficiency, bead morphology, in vitro release, and in vivo gastric retention were evaluated. The optimized formulation via Box-Behnken design consisted of 1.7% alginate (W/V), 1.02% carrageenan (W/V), 1.4% CaCO (W/V), and a gelling bath of pH 0.8. The alginate-carrageenan-Brucea javanica oil beads had a porous structure and exhibited up to 24 h of in vitro floatability with a load capacity of 45%-55% and an encapsulation efficiency of 70%-80%. A 6-h sustained release was observed in vitro. The beads had a prolonged gastric retention (> 60% at 6 h) in fasted rats, compared to non-floating beads (15% at 6 h), as measured by gamma scintigraphy with single-photon emission tomography/computed tomography (SPET/CT). In conclusion, the alginate-carrageenan-Brucea javanica oil system showed enhanced oil encapsulation efficiency, excellent floating and gastric retention abilities, and a favorable release behavior.

Combining Usage of Chemotherapy and Intrapleural Injection with Brucea Javanica Oil in Malignant Pleural Effusion / 医学研究杂志

Objective To study their efficacy and safety of combining usage of chemotherapy and intrapleural injection with brucea javanica oil in treatment of malignant pleural effusion (MPE).Methods 90 NSCLC patients with MPE in Nanjing Chest Hospital between February 2012 and October 2016 were randomly divided into control and treatment group.Subjects in control group were treated with chemotherapy,while those in treatment group were chemotherapy plus intrapleural injection with brucea javanica oil.Both clinical efficacy and adverse reactions were compared.Results By Combining usage of brucea javanica oil,the treatment group has higher effective rate (86.67％ vs 64.44％),lower pathology rate than control groups (P ＜0.05).The main toxicity,matological toxicity,gastrointestinal tract side reaction fever and chest pain was tolerated.There was no significant difference between two groups(P ＞ 0.05).Conclusion Combining usage of brucea javanica oil and chemotherapy in treatment of MPE was safe and effective,which can remarkably inhibit the growth of tumor,promote pleural adhesions and relief symptom.

Effect of bladder instillation of drugs on postoperative recurrence of superficial bladder cancer / 中国基层医药

Objective To compare and analyze the Brucea javanica oil emulsion,hydroxy camptothecin bladder perfusion of recurrence after operation of superficial bladder cancer.Methods 80 cases with superficial blad-der cancer were randomly divided into group A and group B (n=40 ).Group A received intravesical instillation of Brucea javanica oil emulsion,group B received intravesical instillation of hydroxycamptothecin.The serum tumor marker levels were compared between two groups,and the recurrence rate and adverse reactions in the two groups were observed.Results At 1 day before operation,postoperative 7d,the serum Dickkopf-1 (DKK-1 ),Dickkopf-2 (DKK-2),Dickkopf-3(DKK-3),Dickkopf-4(DKK-4),vascular endothelial growth factor A(VEGFA), vascular endothelial growth factor B(VEGFB),vascular endothelial growth factor C(VEGFC)of the two groups had no statistically significant differences (P>0.05).Postoperative 6 months,the serum levels of DKK-1,DKK-2, DKK-3,DKK-4,VEGFA,VEGFB,VEGFC in group A were (20.62 ±2.84)g/L,(29.15 ±6.32)g/L,(18.66 ± 4.53)g/L,(32.34 ±6.42)g/L,(80.72 ±9.16)g/L,(60.43 ±16.73)g/L,(70.31 ±8.41)g/L,respectively, which were lower than those of group B [(27.42 ±3.76)g/L,(38.16 ±4.34)g/L,(30.37 ±5.35)g/L,(47.26 ± 7.72)g/L,(146.31 ±12.44)g/L,(83.14.14.07)g/L,(91.58 ±7.82)g/L,respectively,t=-2.92,-2.58,-2.82,-2.41,-2.80,-2.75,-2.70,all P<0.01].The recurrence rate of group A was 7.5%(3/40),which was significantly lower than 15.0%(6/40)of group B(6/40)(χ2 =6.11,P <0.05).The incidence rate of adverse reac-tions of group A was 12.5%,which was significantly lower than 27.5% of the control group(χ2 =5.46,P<0.05). Conclusion Compared with hydroxyl camptothecine vesical perfusion,the effect of intravesical instillation of Brucea javanica oil emulsion in preventing the postoperative recurrence of superficial bladder cancer is more significant,can effectively reduce the levels of serum tumor marker,with less adverse reactions,it is worth application and promotion.

Clinical Observation on Brucea Javanica Oil Combined with Gemcitabine and Cisplatin in the Treatment of Advanced NSCLC / 中国药房

OBJECTIVE:To observe clinical efficacy and safety of Brucea javanica oil combined with gemcitabine and cisplat-in in the treatment of advanced non small cell lung cancer(NSCLC). METHODS:Totally 131 advanced NSCLC patients selected from Huanggang Hospital of TCM during Feb. 2014 to Jan. 2016 were divided into observation group(71 cases)and control group (60 cases)according to random number table. Control group was given Gemcitabine for injection(1st and 8th day)+Cisplatin injec-tion (2nd day),every 21 days,twice as a treatment course. Observation group was additionally given Breucea javanica oil oral emulsion 20 mL,po,2-3 times/d,for consecutive 14 d (3 days before chemotherapy). Both groups received treatment for 87 d and followed up until Jul. 1,2016. Clinical efficacy,the levels of T cell subsets (CD3+,CD4+,CD8+),survival time were ob-served in 2 groups. Single factor and multiple factor analysis was conducted for survival time. The occurrence of ADR was record-ed. RESULTS:The total response rate of observation group (32.39%) was higher than that of control group (25.00%),without statistical significance(P>0.05). Before treatment,there was no statistical significance in the levels of CD3+,CD4+ and CD8+ be-tween 2 groups(P>0.05). After treatment,the levels of CD3+ and CD4+ in observation group were increased significantly,while CD8+ level was decreased significantly;there was statistical significance compared to control group at corresponding period (P0.05). Single factor analysis showed that the survival time of patients aged 0.05). CONCLU-SIONS:Brucea javanica oil combined with gemcitabine and cisplatin in the treatment of advanced NSCLC patients,although not significantly improve the therapeutic effect,but can significantly improve the cellular immune function. With or without pleural effu-sion and age are infuential facters for survival time of advanced NSCLC patients.

Study on paclitaxel-oleic acid and Brucea javanica oil core-matched nanoemulsions drug delivery / 中草药

Objective: To optimize the preparation method of paclitaxel-oleic acid (PTX-OA)/Brucea javanica oil (BJO) core- matched nanoemulsions (CMNEs). Methods: PTX-OA/BJO was synthesized by esterification of PTX and OA, and determined by HPLC. Ultrasionic emulsification was used to prepare the PTX-OA/BJO CMNEs. The concentration of oil phase (A), quality of polysorbate 80 (B), and ultrasonic power (C) were selected as the significant factors after single-factor experiments and applied in L16(43) orthogonal array design with the average particle size as criterion. In addition, the physicochemical properties and cytotoxicity of PTX-OA/BJO CMNEs were tested. Results: Linear range of PTX-OA was 5-25 μg/mL, Y = 12.709 X + 6.252 0, r = 0.999 5. The optimized conditions of PTX-OA/BJO CMNEs were as follows: The concentration of oil phase was 6.50 mg/mL, the mass ratio of polysorbate 80 to oil phase was 3.5: 6.5 and the ultrasonic power was 120 W. The CMNEs prepared by the optimal conditions showed an entrapment efficiency of (100.6 ± 1.9)% and the nanoscale particle size was (108.7 ± 2.3) nm, PDI was 0.232 ± 0.038. The morphology of CMNEs examined by TEM exhibited a uniform and spherical shape. In vitro drug release was up to 67% after 48 h. After PTX-OA/BJO CMNEs sealed in a bottle were stored at 4 ℃ for 60 h, the average particle size and entrapment efficiency had no significant change. The cytotoxicity in vitro showed that the combined PTX-OA/BJO CMNEs could obviously inhibit the proliferation of HepG-2 cells. Conclusion: The current study demonstrates the feasibility of incorporating PTX-OA and BJO into a single CMNEs for the synergism in cancer therapy. Furthermore, the preparation of PTX-OA/BJO CMNEs has the advantages of practicability and simple operation, as well lays the foundation for the further mechanism research of the combined paclitaxel and BJO in oncotherapy.

Clinical Efficacy and Safety of Brucea javanica Oil Emulsion Injection Combined with GP Regimen Treating Non-small Cell Lung Cancer: A Meta-analysis / 世界科学技术-中医药现代化

This study was aimed to systematically evaluate the clinical efficacy and safety of brucea javanica oil emulsion injection combined with gemcitabine plus cisplatin (GP) regimen in the treatment of non-small cell lung cancer.Literatures were retrieved from databases of CNKI,Wanfang database,VIP,CBM,Pubmed from the date of database establishment to March 2017.Journals on related fields were also manually searched.The randomized controlled trials (RCTs) of brucea javanica oil emulsion injection combined with GP regimen in the treatment of non-small cell lung cancer were collected.The results showed that there were 12 included RCTs with 1 118 patients.The meta-analysis results showed that compared with single using of GP regimen,there were statistical significance in the partial remission rate [OR =1.59,95％ CI (1.23,2.05),P =0.000 4],the total remission rate [OR =1.72,95％ CI (1.33,2.22),P ＜ 0.000 1],the KPS (Karnofsky) score improvement [OR =2.59,95％ CI (1.96,3.43),P ＜ 0.000 01],the deterioration of KPS score [OR =0.33,95％ CI (0.25,0.46),P ＜ 0.000 01],the incidence of bone marrow suppression [OR =0.48,95％ CI (0.35,0.65),P ＜ 0.000 01],and the incidence of gastrointestinal adverse reactions [OR =0.46,95％ CI (0.23,0.91),P =0.03] by brucea javanica oil emulsion injection combined with GP regimen in the treatment of non-small cell lung cancer.It was concluded that brucea javanica oil emulsion injection combined with GP regimen can increase clinical efficacy,decrease myelosuppression rate and gastrointestinal adverse reactions.

Research of Brucea javanica against cancer / 中国结合医学杂志

Brucea javanica, a Chinese herbal medicine, combined with conventional anticancer modalities, has been widely used for treatment of various cancers. Based on researches over the last decades, authors briefly summarized its active constituents, molecular mechanisms and clinical application for cancer treatment.

Protein composition analysis and cytotoxicity of gulbulin hydrolysates of Brucea javanica seeds / 中国中药杂志

To analyze the protein composition of Brucea javanica seeds and evaluate the cytotoxicity of its gulbulin hydrolysates. Four protein fractions of albumin, gulbulin, prolamin and glutelin were sequentially extracted and then quantified by Kjeldahl method. Different kinds of proteases were applied to hydrolyze B.javanica gulbulin, and MTT assay was used to evaluate the cytotoxicity of low molecular weight hydrolysates (≤3 kDa) on human breast cancer MCF-7 cell. The results showed that： the total protein content of B.javanica seeds was 17.47%, albumin, gulbulin, coxin, glutelin and residue protein accounted for 15.01%, 8.11%, 2.47%, 44.92% and 23.62% of the total protein content, respectively. The hydrolysates (≤3 kDa) of B.javanica globulin produced by pepsin showed significant growth inhibitory activity on MCF-7 cells, and the IC₅₀ value was（6.52±0.01） mg•L⁻¹ after 72 h of incubation. Protein was abundant in B.javanica seeds, and its peptides demonstrated specific cytotoxicity on MCF-7 cell line in vitro, suggesting antitumor active ingredient can be further generated from B.javanica seeds.

Meta-analysis on efficacy and safety of Brucea javanica oil emulsion injection combined with chemotherapy for patients with advanced gastric carcinoma / 中国中药杂志

Eligible studies were searched in Cochrane library, Pubmed, Medline, CBM, CNKI and VIP databases from establishment to June 2014. Two researchers independently identified 7 randomized controlled trials (RCTs) and extracted data of Brucea javanica oil emulsion injection combined with chemotherapy. Based on the published studies, the researchers analyzed them by RevMan 5.2 software and investigated the efficacy and safety of Brucea javanica oil emulsion injection combined with chemotherapy for patients with advanced gastric cancer by Meta analysis. Meta analysis showed that, compared with the simple chemotherapy, Brucea javanica oil emulsion injection combined with chemotherapy could increase objective response rate by 43%(RR=1.43, P<0.001). In addition, the incidence of neutropenia (RR=0.56, P<0.001), thrombocytopenia (RR=0.64, P=0.02), nausea, vomit (RR=0.66, P=0.002) decreased in these patients. However, the quality of life was not improved significantly in gastric carcinoma patients with combined therapy (RR=1.36, P=0.07). The paper suggested Brucea javanica oil emulsion injection combined with chemotherapy could increase efficacy and safety, which might be a promising therapy for patients with advanced gastric cancer.

Systematic evaluation of brucea javanica oil adjuvant therapy of primary hepatocellular carcinoma / 中国医师杂志

Objective To review the efficacy and safety of brucea javanica oil in the adjuvant therapy of primary hepatocellular carcinoma (HCC).Methods China National Knowledge Infrastructure (CNKI),China Biology Medicine (CBM),VIP,Wanfang database,Pubmed,Web of Science,ScienceDirect,and Cochrane Library were searched from their inception to December 2015.Then contact with the field experts and correspondence authors for gray literature.Two reviewers independently searched the databases,performed data extraction,and appraised the publications.The Reviewer Manager 5.3 software was employed for data analysis.Results Fifteen clinical trials with 1 128 HCC patients were included.Meta-analysis confirmed that the brucea javanica oil group,compared to the control group,was more advantageous to reduce the incidence of postoperative fever,bone marrow suppression,and gastrointestinal reaction.In addition,it might reduce the level of alpha fetoprotein (AFP),enhance immunity,and improve clinical symptoms.However,more evidence would be needed to support these results.Conclusions Brucea javanica oil is considered to reduce toxicity and increase efficiency in the adjuvant therapy for the HCC,but more high quality,multi-center,large sample,randomized,double-blind clinical trials are also needed for supporting this view.

The research progress of quassinoids components in Brucea javanica and their pharmacological activities / 中国药理学通报

Fructus Bruceae, the dry and ripe fruits of Brucea ja-vanica( L. ) Merr. ( Simaroubaceae) , has been used for dysenter-y, tumor, malaria and furunculosis treatment, and topical appli-cation for warts and corns. Quassinoids are the main chemical constituents of Fructus Bruceae, which have been proved to have anti-tumor, anti-inflammatory, insecticidal, anti-viral, anti-bac-terial and hypoglycemic activities, and so on. In view of the ex-tensive pharmacological activities of Fructus Bruceae, and better development and utilization of its medicinal value, the advances of quassinoids in Fructus Bruceae and their pharmacological ac-tivities are reviewed in this paper.

Clinical observation of brucea javanica oil combined with 125I and chemotherapy on Stage Ⅲ-Ⅳ Pa-tients with non-small cell lung cancer / 中国综合临床

Objective To investigate the clinical efficacy and side reaction of brucea javanica oil ( BJO) combined with 125I and chemotherapy on stageⅢ?Ⅳpatients with non?small cell lung cancer ( NSCLC) . Methods One hundred and twenty cases on stageⅢ?Ⅳpatients with NSCLC were randomly divided into two groups,60 cases received BJO combined with 125I and chemotherapy treatment(observation group),the other 60 cases received 125I combined with chemotherapy treatment(control group). Results The objective response rate(ORR) and disease control rate (DCR) were 71. 7%,86. 7% of observation group and 66. 7%,85. 0% of control group,there were no significant difference(χ2=0. 352,0. 069;P>0. 05) . The improvement rate of KPS score in observation group was significantly superior to that in control group, the difference was significant (76. 7% vs. 55. 0%;χ2=6. 261,P<0. 05) . The incidence of myelosuppression and gastrointestinal adverse e?vents in observation group was significantly lower that in control group ( 68. 3% vs. 83. 3%,41. 7% vs. 61. 7%;χ2=3. 883,4. 805;P<0. 05) . Conclusion BJO combined with 125I and chemotherapy for treating on stageⅢ?Ⅳ patients with NSCLC can reduce the toxicity and side effects caused by chemotherapy,and significantly im?prove the clinical symptoms and quality of life of patients.

Effect of brucea javanica oil emulsion combined with radiotherapy for the treatment of patients with esophageal cancer / 肿瘤研究与临床

Objective To evaluate the efficacy and untoward effects of brucea javanica oil emulsion combined with radiotherapy in the treatment of patients with esophageal cancer. Methods 50 initial treatment patients with esophageal squamous cell carcinoma were randomly assigned to observation group (25 cases) and control group (25 cases). All patients were treated with three dimensional conformal intensity modulated radiation therapy (3D-IMRT) and the radiation dose was 64 Gy/32 times (95 % PTV). The patients in observation group received the treatment of brucea javanica oil emulsion during radiotherapy. The differences between the two groups were compared in respect of the efficacy, the adverse reactions and the quality of life (QOL). Results The effective rate in observation group was 92%(23/25) and it was 68%(17/25) in control group, there was significant difference between the two groups (χ2 = 4.500, P= 0.034). The incidence of radiation esophagitis at the level of RTOG2 and above in observation group was 20%(5/25) and it was 60%(15/25) in the control group, there was significant difference between the two groups (χ2= 8.333, P=0.004). The improvement rate of QOL in observation group was 68 % (17/25) and it was 40 % (10/25) in control group, there was significant difference between the two groups (χ2 = 3.945, P= 0.047). Conclusion Brucea javanica oil emulsion combined with radiotherapy for the treatment of patients with esophageal cancer can improve the therapeutic effect and QOL,it can also reduce radiation reactions.

Clinical observation of double -way chemotherapy on brucea javanica oil emulsion combined with TP regi-men in treating malignant pleural effusion of NSCLC / 中国基层医药

Objective To evaluate short -term clinical efficacy and adverse effects of brucea javanica oil emulsion(BJOE)combined with TP regimen in treating malignant pleural effusion(MPE)of non -small cell lung cancer(NSCLC)by double -way chemotherapy.Methods Totally 91 patients with MPE of NSCLC diagnosed by pathology were builted into the central venous catheter.The patients were assigned to group A,B and C according to therapies.Group A(21 cases)accepted infusion of BJOE 60mL into thoracic cavity twice a week.Group B(33 cases) accepted TP regime therapy,which included paclitaxel(TAX)intravenous chemotherapy at a dose of 150mg/m2 and cisplatin(DDP)injecting into thoracic cavity at a dose of 60mg +0.9% sodium chloride injection 30mL in first day, the therapy was repeated every 3 weeks.Group C(38 cases)combined the therapies of group A′s and B′s.Clinical efficacy and adverse effects were evaluated after 6 weeks.Results The objective response rate(81.6%)for group C was higher than group A or B(χ2 =8.605,P <0.05),the same result were in CR ratio(55.3%)(χ2 =10.384,P <0.05)and PD ratio(5.3%)(χ2 =8.649,P <0.05).There were no serious adverse effects in the three groups.The occurring rate of white blood cell reduction in group A was lower than those of group B and C,there was statistically significance(χ2 =8.999,P <0.05).Conclusion The efficacy of BJOE combined with TP regimen in treating MPE of NSCLC by double -way chemotherapy is better than that of single chemotherapy or alone intrathoracic treatment, and the adverse effects could be well tolerated.